Compare AbCellera Biologics Inc (ABCL) vs Allegion PLC (ALLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Allegion PLC — how do they compare? AbCellera Biologics Inc trades at $9.98 (market cap $2.99B), while Allegion PLC trades at $165.98 (market cap $14.32B). The key difference: Allegion PLC is far larger — about 4.8× AbCellera Biologics Inc's market cap, and Allegion PLC pays a 1.26% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ALLE | |
|---|---|---|
Market Cap | $2.99B | $14.32B |
Sector | Health | Industrials |
52-Week High | $9.76 | $179.77 |
52-Week Low | $2.78 | $125.65 |
Enterprise Value | $2.58B | $16.03B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Allegion (ALLE) trades at $165.53, down 2.02% today, near its consensus price target of $156. The stock shows bullish technical momentum with strong moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported robust Q2 2026 results with EPS of $2.40 beating estimates and revenue growth of nearly 13% year-over-year, driven by strength in its Americas segment. It maintains solid profitability with a net income margin of 15.36% and ROE of 33.73%.
The outlook is positive, supported by raised full-year guidance and institutional buying, but risks include high valuation multiples and reliance on Americas market growth. Analyst sentiment is mixed with a 'Hold' consensus, indicating cautious optimism amid strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →
